Short answer
Allogene Therapeutics, Inc. (ALLO) filed an 8-K current report with the SEC on June 22, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 8.01 (Other Events). Stockholders elected Deborah Messemer, Vicki Sato and Owen Witte as Class II directors through the 2029 annual meeting.
Allogene Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders elected Deborah Messemer, Vicki Sato and Owen Witte as Class II directors through the 2029 annual meeting
- Executive compensation approved with 213,098,167 votes, supporting current pay practices
- Board adopted annual say-on-pay votes through no later than the 2032 annual meeting
- Authorized common shares doubled from 400,000,000 to 800,000,000, enabling future financing or equity issuance
- Ernst & Young ratified as independent auditor for fiscal 2026 with 282,022,884 votes in favor
Item 8.01 · Other Events
- $135.0 million at-the-market equity offering capacity under the existing Sales Agreement
- TD Securities (U.S.A.) LLC serving as sales agent
- Potential shareholder dilution from future common-stock sales
- Equity proceeds provide Allogene additional financing flexibility without new debt્રીય
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Allogene Therapeutics, Inc. 8-K filings
Get the next ALLO 8-K as it lands
Follow ALLO for push alerts, or ask the research agent what this filing means.